DJ Affluent Medical announces coverage initiation of its stock by Portzamparc - Groupe BNP Paribas.
Affluent Medical
Affluent Medical announces coverage initiation of its stock by Portzamparc - Groupe BNP Paribas.
27-Nov-2023 / 07:30 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
PRESS RELEASE
Affluent Medical announces coverage initiation of its stock by Portzamparc - Groupe BNP Paribastifs
Aix-en-Provence, November 27, 2023 - 7:30 am CEST- Affluent Medical (ISIN code: FR0013333077 - ticker: AFME), a French
clinical-stage MedTech company specializing in the international development and industrialization of innovative
medical prostheses, announces today that Portzamparc - Groupe BNP Paribas has initiated coverage of its stock.
Portzamparc - BNP Paribas Group began covering the stock with a study entitled "Au plus proche de votre coeur" ("Closer
to your heart"), published on November 24, 2023. In this study, Portzamparc - BNP Paribas Group recommended buying the
stock, with a target price of EUR3.60, representing a potential upside of 188% compared with the closing price on
November 23, 2023.
This initiation completes the coverage of Affluent Medical's stock and adds to the financial analyst consensus
alongside Invest Securities and Kepler Cheuvreux.
About Affluent Medical
Affluent Medical is a French MedTech company, founded by Truffle Capital, with the ambition to become a global leader
in the treatment of structural heart diseases, which are the world's leading cause of mortality, and urinary
incontinence, which currently affects one in four adults.
Affluent Medical develops next-generation, mini-invasive, innovative, adjustable, and biomimetic implants to restore
critical physiological functions. The product candidates developed by the Company are currently in preclinical and
clinical studies.
Kalios, the first mitral adjustable annuloplasty ring, should be the first Affluent Medical device to be marketed.
Subject to raising the necessary funds to finance its strategy and to positive results from ongoing clinical studies,
the Company's ambition is to gradually commercialize its products from the end of 2025/early 2026.
For more information, visit www.affluentmedical.com
Contacts:
AFFLUENT MEDICAL SEITOSEI.ACTIFIN
Financial communications / press relations
Sébastien Ladet Ghislaine GASPARETTO / Jennifer JULLIA
Chief Executive Officer +33 (0)6 21 10 49 24 / +33 (0)1 56 88 11 19
investor@affluentmedical.com affluentmedical@actifin.fr / jjullia@actifin.fr
MC SERVICES AG
PRIMATICE
Media relations Europe
Media relations France
Thomas Roborel de Climens Caroline Bergmann / Kirsten RÜHL
+33 (0)6 78 12 97 95
+49 (0)211 529252 20 / +49 (0)211 529252 16
thomasdeclimens@primatice.com
affluent@mc-services.eu
-----------------------------------------------------------------------------------------------------------------------
Regulatory filing PDF file File: Affluent Medical - Portzamparc EN
=------------------------------------------------------------------
Language: English
Company: Affluent Medical
320 avenue Archimède, Les pléiades III Bâtiment B
13100 Aix en Provence France
France
Phone: +33 4 42 95 12 20
E-mail: jerome.geoffroy@affluentmedical.com
Internet: https://www.affluentmedical.com/
ISIN: FR0013333077
Euronext Ticker: AFME
AMF Category: Inside information / Other releases
EQS News ID: 1781921
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
1781921 27-Nov-2023 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1781921&application_name=news
(END) Dow Jones Newswires
November 27, 2023 01:30 ET (06:30 GMT)
© 2023 Dow Jones News
